MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Voyager Therapeutics Inc

Затворен

3.41 1.19

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.27

Максимум

3.51

Ключови измерители

By Trading Economics

Приходи

-25M

-34M

Продажби

-18M

6.3M

P/E

Средно за сектора

6.415

63.778

EPS

-0.59

Марж на печалбата

-549.331

Служители

172

EBITDA

-25M

-37M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+343.7% upside

Дивиденти

By Dow Jones

Следващи печалби

12.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-31M

202M

Предишно отваряне

2.22

Предишно затваряне

3.41

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

Voyager Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

29.10.2024 г., 21:31 ч. UTC

Топ новини

AbbVie's Deal for Alzheimer's Antibody Raises Curtain for Roche News on Wednesday -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Voyager Therapeutics Inc Прогноза

Ценова цел

By TipRanks

343.7% нагоре

12-месечна прогноза

Среден 15.13 USD  343.7%

Висок 30 USD

Нисък 9 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Voyager Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

10

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

3.26 / 3.74Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Weak Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.